13 August 2019 | News
DUROLANE, a single-injection, hyaluronic acid product used for joint lubrication in the treatment of pain associated with knee osteoarthritis, now has expanded indications in Australia and New Zealand
Bioventus, a global leader in orthobiologic solutions, is launching DUROLANE SJ (1mL), and has received expanded indications for DUROLANE (3mL), its single-injection joint-fluid osteoarthritis (OA) treatment, in Australia and New Zealand. Both are hyaluronic acid (HA)-based products and available from LMT Surgical.
DUROLANE SJ (1mL) has been approved by Australia’s Therapeutic Goods Association (TGA) and MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, and will launch in both countries later this year. It is indicated for symptomatic treatment associated with mild to moderate OA pain in the ankle, elbow, wrist, fingers, and toes. DUROLANE SJ (1mL) is also indicated for pain following joint arthroscopy in the presence of OA within three months of the procedure.
In addition, DUROLANE (3mL), which has been indicated for symptomatic treatment of mild to moderate knee OA pain in both countries for several years, received approval for expanded indications by both the TGA and MEDSAFE. These include symptomatic treatment of mild to moderate hip OA and the symptomatic treatment associated with mild to moderate OA pain in the ankle, shoulder, elbow, wrist, fingers, and toes. DUROLANE (3mL) is also indicated for pain following joint arthroscopy in the presence of OA within three months of the procedure.
“More than two million Australian citizens suffer from some form of osteoarthritis,” said John Nosenzo, Chief Commercial Officer, Bioventus. “The availability of DUROLANE SJ, and the expanded indications for DUROLANE, gives them, and OA patients in New Zealand, even more options for OA pain relief.”
“We are excited to work with Bioventus and introduce both DUROLANE and DUROLANE SJ to more patients seeking OA pain relief,” said Kerry Lawford, Managing Director, LMT Surgical. “In addition, physicians now have more choices regarding appropriate volumes of HA for each affected joint.”
“DUROLANE is the original single-injection HA treatment for knee OA and has a great track record in Australia and New Zealand,” said Andrew McCartney, Managing Director, International, Bioventus. “The broadened indications of the product, combined with the service offerings from LMT Surgical and its strong presence throughout the market, give us the opportunity to treat more OA patients than ever before.”
OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues andHA-based products like DUROLANE, help manage OA pain for patients. DUROLANE is non-avian and based on the safe, natural and unique NASHA® technology. NASHA yields stabilized HA which is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint.